| Lung Non-Small Cell Carcinoma17 |
|---|
| EGFR Mutation | Afatinib | Predictive | B | Supports Sensitivity Response | 4 | accepted | EID1728In the LUX-LUNG 7 trial, (NCT01466660) stage IIIB or IV NSCLC patients with EGFR exon 19 deletion, (n=186) Leu858Arg mutation, (n=132) or both (n=1) were divided into equal groups and treated with fir… (full text at CIViC) PMID 27083334 · Park et al., 2016 · Open in CIViC | civic |
| EGFR Mutation | Afatinib | Predictive | B | Supports Sensitivity Response | 4 | accepted | EID2153In a phase 2b/3 study of 585 stage IIIB-IV lung adenocarcinoma patients who had a previous round of EGFR-TKI treatment, archival material was available for 141 patients. EGFR mutational analysis revea… (full text at CIViC) PMID 22452896 · Miller et al., 2012 · Open in CIViC | civic |
| EGFR Mutation | Afatinib | Predictive | D | Supports Sensitivity Response | 3 | submitted | EID12780An in vitro study transformed Ba/F3 murine cells (IL-3 dependent lymphocyte model) with one of five uncommon EGFR mutations: Del18 (delE709_T710insD), E709K, G719A, S768I, and L861Q. The response to c… (full text at CIViC) PMID 40940797 · Oiki et al., 2025 · Open in CIViC | civic |
| EGFR Mutation | Amivantamab + LazertinibCombination | Predictive | B | Supports Sensitivity Response | 3 | submitted | EID12928This clinical study focuses on 105 participants included in the CHRYSALIS-2 Cohort (Cohort C), examining the treatment outcome of atypical EGFR mutation non-small cell lung cancer (NSCLC) to a combine… (full text at CIViC) PMID 41325571 · Tomasini et al., 2025 · Open in CIViC | civic |
| EGFR Mutation | Datopotamab Deruxtecan | Predictive | A | Supports Sensitivity Response | 4 | accepted | EID12523TROPION-Lung01 (NCT04656652) was a global, randomized, open-label phase III trial of 604 patients with previously treated advanced NSCLC comparing datopotamab deruxtecan (Dato-DXd) with docetaxel. Dat… (full text at CIViC) PMID 39250535 · Ahn et al., 2025 · Open in CIViC | civic |
| EGFR Mutation | Datopotamab Deruxtecan Regimen | Predictive | A | Supports Sensitivity Response | 4 | accepted | EID12522Phase II trial (NCT04484142) of Dato-DXd 6 mg/kg every 3 weeks in 137 heavily pretreated patients with advanced NSCLC harboring actionable genomic alterations (57% EGFR-mutant; 51% with prior brain me… (full text at CIViC) PMID 39761483 · Sands et al., 2025 · Open in CIViC | civic |
| EGFR Mutation | Erlotinib | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID3794In a phase II trial for Bronchioloalveolar carcinoma (BAC, or in situ pulmonary adenocarcinoma), EGFR exons 18-24 were analyzed in 7 patients who had shown a partial response to Erlotinib, and 10 pati… (full text at CIViC) PMID 15329413 · Pao et al., 2004 · Open in CIViC | civic |
| EGFR Mutation | Erlotinib | Predictive | B | Supports Sensitivity Response | 4 | accepted | EID7024In this open-label, randomised, phase 3 trial at 22 centres in China, patients with stage IIIB or IV NSCLC who had exon 19 deletion or exon 21 L858R point mutation, and who had not received previous s… (full text at CIViC) PMID 21783417 · Zhou et al., 2011 · Open in CIViC | civic |
| EGFR Mutation | Erlotinib | Predictive | C | Supports Sensitivity Response | 4 | accepted | EID4201In the placebo-controlled Phase III study SATURN, using erlotinib maintenance therapy for patients with advanced NSCLC who were selected for response or stable disease after first line chemotherapy, E… (full text at CIViC) PMID 21969500 · Brugger et al., 2011 · Open in CIViC | civic |
| EGFR Mutation | Gefitinib | Predictive | B | Supports Sensitivity Response | 5 | accepted | EID1937This open label Phase 3 Trial performed across 36 centers in Japan (WJTOG3405) assessed patients with postoperative recurrent or stage IIIB/IV NSCLC and activating EGFR mutations (Exon 19 deletion and… (full text at CIViC) PMID 20022809 · Mitsudomi et al., 2010 · Open in CIViC | civic |
| EGFR Mutation | Gefitinib | Predictive | B | Supports Sensitivity Response | 5 | accepted | EID2148In a phase 3 clinical trial of East Asian advanced pulmonary adenocarcinoma patients, a subset of patients with EGFR mutations (n=261) treated with gefitinib were associated with improved response (HR… (full text at CIViC) PMID 19692680 · Mok et al., 2009 · Open in CIViC | civic |
| EGFR Mutation | Gefitinib | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID2559Mutational profiling was performed on EGFR exons 18-24 from a group of 10 retrospectively chosen patients who had shown partial response or clinical imporvement in response to gefitinib, and in 8 pati… (full text at CIViC) PMID 15329413 · Pao et al., 2004 · Open in CIViC | civic |
| EGFR Mutation | Gefitinib | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID3016In a phase 3 clinical trial of non-small cell lung cancer (NSCLC) patients, a subset of patients with EGFR mutations (n=44) treated with gefitinib were associated with improved progression free surviv… (full text at CIViC) PMID 20038723 · Douillard et al., 2010 · Open in CIViC | civic |
| EGFR Mutation | Afatinib + GefitinibSubstitutes | Predictive | D | Supports Resistance | 3 | submitted | EID6465Three major drug resistance mutations, namely L718Q, L844V, and C797S were identified in EGFR and caused resistance to both WZ4002 and CO-1686. In contrast, only EGFR C797S caused AZD9291 resistance.… (full text at CIViC) PMID 25948633 · Ercan et al., 2015 · Open in CIViC | civic |
| EGFR Mutation | Erlotinib + GefitinibSubstitutes | Predictive | B | Supports Sensitivity Response | 4 | accepted | EID2053In a retrospective study, 166 non-small cell lung cancer (NSCLC) patients that tended to have selected characteristics known to be predictive for TKI sensitivity (i.e. women, never smokers, and patien… (full text at CIViC) PMID 21258250 · Ludovini et al., 2011 · Open in CIViC | civic |
| EGFR Mutation | Gefitinib + PemetrexedCombination | Predictive | B | Supports Sensitivity Response | 3 | submitted | EID7650A phase 2 study was conducted to compare treatment with pemetrexed and gefinitib (P+G) versus gefinitib monotherapy for a population of 195 East Asian non-squamous NSCLC patients with EGFR mutations (… (full text at CIViC) PMID 31605797 · Yang et al., 2020 · Open in CIViC | civic |
| EGFR Mutation AND ( MET Amplification OR MET Overexpression ) | Gefitinib + TepotinibCombination | Predictive | B | Supports Sensitivity Response | 2 | submitted | EID11456This phase 1b/2, multicentre, randomized clinical trial was conducted on the combination of tepotinib and gefitinib on patients with MET overexpression or MET amplification that showed resistance to E… (full text at CIViC) PMID 32479794 · Wu et al., 2020 · Open in CIViC | civic |